From: Mannitol as adjunct therapy for childhood cerebral malaria in Uganda: A randomized clinical trial
Variable | Placebo N = 80 | Mannitol N = 76 | P value |
---|---|---|---|
Female | 42(52.5%) | 34(44.7%) | 0.33 |
Fever | 79(98.8) | 76 (100%) | 0.33 |
Convulsions | 79(98.8%) | 75(98.7%) | 0.97 |
Duration of coma | 7.0 (IQR3.5–12.0) | 6.0 (5.0–12.0) | 0.79 |
Blantyre coma score 1/5 | 13(16.2%) | 10(13.2%) | 0.59 |
Abnormal fundoscopic changesa | 28(35.0%)) | 16(21.1%) | 0.53 |
Papilloedema | 3(3.8%) | 5(6.6%) | 0.42 |
Sodium – mmol/l (SD) | 133.8 (4.2) | 130.9 (14.8) | 0.09 |
Hb – g/dl (SD) | 7.1 (1.8) | 7.1 (1.9) | 0.98 |
Parasite density/μL (IQR) | 37000(5390–115760) | 58860(12390–284590) | 0.05 |